MicroVAX, LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
May 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 20, 2027The maintenance fee for Vaccine directed to induction of immune response to protein and glycolipid antigens of bacterial cells through interaction of CD4OL/CD40 receptor axis with complex of glycolipid/CD1d receptor in NKT cells and in dendritic cells (US 10,383,932) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
- 1 fee due Jun 12, 2027The maintenance fee for Combination cancer therapy (US 11,839,655) comes due Jun 12, 2027. Unpaid by Dec 13, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 21, 2026
- Nov 17 US 12,797,454 mRNA VACCINE DESIGN USING MULTIPLE INTERACTING IMMUNO-STIMULATORY PATHWAYS, FOR CANCER AND INFECTIOUS DISEASES
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 6 of 6
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,383,932 | Vaccine directed to induction of immune response to protein and glycolipid antigens of bacterial cells through interaction of CD4OL/CD40 receptor axis with complex of glycolipid/CD1d receptor in NKT cells and in dendritic cells In force · USPTO record | In force | USPTO record | |
| US 10,149,899 | Composition and Method Against C-Difficile In force · High confidence | In force | High confidence | |
| US 10,166,284 | Vaccines for Herpes Simplex Virus 1 and 2 In force · High confidence | In force | High confidence | |
| US 11,839,655 | Combination cancer therapy In force · USPTO record | In force | USPTO record | |
| US 12,427,191 | SARS-CoV-2 fusion protein vaccine/regimen In force · USPTO record | In force | USPTO record | |
| US 12,797,454 | mRNA VACCINE DESIGN USING MULTIPLE INTERACTING IMMUNO-STIMULATORY PATHWAYS, FOR CANCER AND INFECTIOUS DISEASES In force · High confidence | In force | High confidence |
Also on record, not counted in the 6: 19 lapsed for an unpaid fee · 2 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 no status recorded
Showing 1 to 4 of 4, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. No title is shown: the bulk publication record carries none for these applications, and this site holds no USPTO file history for them.
| Application | Filed | Status |
|---|---|---|
| 18/529,140 | Dec 5, 2023 | No status recorded |
| 17/391,103 | Aug 2, 2021 | No status recorded |
| 14/154,710 | Jan 14, 2014 | No status recorded |
| 13/759,224 | Feb 5, 2013 | No status recorded |